Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m (Jwarner moved page Caplacizumab (ALX-0081) to Caplacizumab (Cablivi): FDA approval) |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
A [https://en.wikipedia.org/wiki/Single-domain_antibody single domain antibody] directed against the A1 domain of von Willebrand factor (vWF). | A [https://en.wikipedia.org/wiki/Single-domain_antibody single domain antibody] directed against the A1 domain of von Willebrand factor (vWF). | ||
| − | = | + | ==Diseases for which it is used== |
| + | *[[Thrombotic thrombocytopenic purpura]] | ||
| − | ==[[Thrombotic thrombocytopenic purpura]]== | + | ==History of changes in FDA indication== |
| − | + | * 2/6/2019: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' ALX-0081 | ||
| + | *'''Generic name:''' caplacizumab-yhdp | ||
| + | *'''Brand name:''' Cablivi | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 14: | Line 20: | ||
[[Category:Thrombotic thrombocytopenic purpura medications]] | [[Category:Thrombotic thrombocytopenic purpura medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2019]] |
Revision as of 19:19, 6 February 2019
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi